CKM Advisor

Who may benefit from an SGLT2 inhibitor, a GLP-1 receptor agonist or a mineralocorticoid receptor antagonist, from current guidelines and FDA labels. Runs in your browser; nothing you enter is sent or stored.

Reviewed by Matthew Abramson, MD ยท November 15, 2026

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.